Of course. Here is a comprehensive English "package insert" or prescribing information summary for Lucius Lenacapavir, modeled on standard pharmaceutical formats.

LUCIUS Lenacapavir [Injection & Tablets]

Prescribing Information Simulation

Disclaimer: This is a simulated summary based on the known pharmacological data of Lenacapavir and generic drug manufacturing standards. It is intended for informational purposes only and does not replace the official prescribing information provided by Lucius Pharmaceutical or the advice of a qualified healthcare professional. Always consult a medical doctor for treatment decisions.

1. TRADE NAME

LUCIUS Lenacapavir

2. COMPOSITION

• Lenacapavir Sodium: Equivalent to 300 mg lenacapavir per oral tablet.

• Lenacapavir Sodium: Equivalent to 463.5 mg lenacapavir per 1.5 mL subcutaneous injection (delivered volume for a 927 mg dose is 3.1 mL from two vials).

3. PHARMACEUTICAL FORM

• Film-coated tablet for oral administration.

• Solution for subcutaneous injection.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications

LUCIUS Lenacapavir, in combination with other antiretroviral drugs, is indicated for the treatment of multidrug-resistant HIV-1 infection in adults who are heavily treatment-experienced with limited treatment options due to resistance, intolerance, or safety considerations.

4.2 Posology and Method of Administration

Administration must be initiated under the guidance of a physician experienced in the management of HIV infection.

The regimen consists of oral loading doses followed by subcutaneous maintenance injections.

• Initiation Therapy (Oral Loading Dose):

  • Day 1: 600 mg (two 300 mg tablets) taken orally with or without food.

  • Day 2: 600 mg (two 300 mg tablets) taken orally with or without food.

• Maintenance Therapy (Subcutaneous Injection):

  • Starting from Day 8: A subcutaneous injection of 927 mg (delivered as two 1.5 mL injections of 463.5 mg each, administered in quick succession at the same visit).

  • Maintenance Interval: Continue with a 927 mg subcutaneous injection every 26 weeks (every 6 months).

Missed Dose:

• If a scheduled subcutaneous injection is missed by more than 28 weeks, the physician should be consulted. Re-initiation with oral loading doses may be required.

4.3 Contraindications

• Hypersensitivity to the active substance or to any of the excipients.

• Coadministration with strong CYP3A inducers: Concomitant use is contraindicated as it may significantly decrease lenacapavir plasma concentrations, reducing its therapeutic effect and leading to possible resistance. Examples include:

  • Rifampicin, rifapentine

  • Carbamazepine, phenytoin

  • St. John's Wort (Hypericum perforatum)

4.4 Special Warnings and Precautions

• Ensure completion of oral lead-in doses before administering the first subcutaneous injection.

• Injection Site Reactions (ISRs) are very common (e.g., pain, erythema, swelling, induration, nodule, pruritus). These are generally mild to moderate and resolve within a few days.

• Potential for hypersensitivity reactions. Discontinue if signs of a severe reaction occur.

• Hepatic Effects: Transient asymptomatic increases in ALT/AST have been observed. Monitor liver enzymes as clinically appropriate.

• Drug Interactions: Lenacapavir is a substrate of CYP3A and P-gp. Coadministration with drugs that are strong or moderate inducers of CYP3A is not recommended. Coadministration with drugs that are strong inhibitors of CYP3A may increase lenacapavir exposure. A comprehensive review of concomitant medications is essential.

4.5 Interaction with other Medicinal Products

Consult a full interaction list before prescribing. Key interactions include:

• Contraindicated: Strong CYP3A inducers (see 4.3).

• Not Recommended: Moderate CYP3A inducers (e.g., bosentan, efavirenz, etravirine, modafinil).

• Use with Caution: Strong CYP3A inhibitors (e.g., clarithromycin, itraconazole, ritonavir) may increase lenacapavir concentration.

4.6 Pregnancy and Lactation

• Pregnancy: There are limited data on use in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

• Lactation: HIV-1 infected mothers should not breastfeed to avoid postnatal transmission of HIV.

4.7 Effects on Ability to Drive and Use Machines

Lenacapavir has no or negligible influence on the ability to drive and use machines. Dizziness has been reported in some patients.

4.8 Undesirable Effects (Adverse Reactions)

Summary based on clinical trials:

• Very Common (≥1/10): Injection Site Reactions.

• Common (≥1/100 to <1/10): Nausea, Diarrhea, Headache, Rash, Pruritus, Fatigue, Pyrexia, Upper respiratory tract infection, Increased transaminases (ALT/AST).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties

• Pharmacotherapeutic group: Antiviral for systemic use, HIV antivirals.

• Mechanism of Action: Lenacapavir is a first-in-class HIV-1 capsid inhibitor. It interferes with the HIV-1 capsid protein at multiple stages of the viral life cycle, including:

  1. Impeding nuclear import of viral DNA and virus replication.

  2. Disrupting the assembly and release of new viral particles.

• Microbiology: It demonstrates activity against HIV-1 isolates resistant to other drug classes.

6. PHARMACEUTICAL PARTICULARS

6.1 Shelf Life

• As stated on the packaging. Typically, injectable solutions require refrigeration.

6.2 Special Precautions for Storage

• Tablets: Store below 30°C in the original package to protect from moisture.

• Injection: Refrigerate at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.

• The injection may be kept at room temperature (up to 30°C/86°F) for a maximum of 30 minutes prior to administration.

6.3 Name and Address of the Marketing Authorization Holder

Lucius Pharmaceutical Co., Ltd.
Address: [Address would be listed here, e.g., Saphanthong Neua Village, Sisattanak District, Vientiane Capital, Lao P.D.R.]

7. MANUFACTURER INFORMATION

Lucius Pharmaceutical is a generic drug manufacturer based in Laos. Its products are registered for use in Laos and may be exported to other countries that recognize its approvals. As with any generic medicine, its bioequivalence to the reference product (Sunlenca® by Gilead) is a key regulatory requirement.